Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elan Seeks Frovelan Partner, More Sales Reps For Migraine Product Launch

Executive Summary

Elan expects to launch the migraine therapy Frovelan this year with a co-promotion partner, VP-Investor Relations John Howarth indicated March 27 at the Banc of America Securities Healthcare Conference in Las Vegas.
Advertisement

Related Content

Elan Frova Migraine Launch To Follow Finalized Co-Marketing Agreement
Elan Frova Migraine Launch To Follow Finalized Co-Marketing Agreement
Andrx To Launch Lovastatin XL In 2002 With 150-Rep Sales Force
SB Relinquishes Frovatriptan Royalties As Final Step In Antitrust Review
SB Relinquishes Frovatriptan Royalties As Final Step In Antitrust Review
Advertisement
UsernamePublicRestriction

Register

PS037582

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel